I always think of why I attend the ACR: to gain new information and knowledge and bring it back to my clinic for my patients. Here's what I'm looking forward to this year.
Dr. Neal Birnbaum Previews ACR 2020 and Predicts the Future
Past ACR President Dr. Neal Birnbaum discusses the pros and cons of a virtual conference ... and predicts what future meetings may look like.
COVID, Artificial Intelligence and Metabolomics at ACR 2020: Dr. Arthur Kavanaugh
Dr. Arthur Kavanaugh provides an overview of the ACR 2020 meeting, including his review of COVID, machine learning (AI) and metabolomics sessions.
Dr. Vibeke Strand previews ACR 2020 highlights, including The Great Debate
Dr. Vibeke Strand discusses opening day at ACR 2020, sessions she's looking forward, and provides a sneak peek into The Great Debate.
Crystal Arthritis and Gout Highlights at ACR: Dr. Nicola Dalbeth
Gout specialist Dr. Nicola Dalbeth from Aukland, New Zealand provides a preview perspective on crystal arthritis and gout studies and sessions at ACR 2020.
From flu shots and face masks to vaccines and searching for the immunological endotype, here are six things rheumatologists need to know about COVID-19.
Pearls for Navigating ACR 2020: Drs. Meral El Ramahi and Kevin Byram
In this video, Dr. El Ramahi talks with Dr. Kevin Byram, on his thoughts about maximizing participation in ACR, vasculitis and other sessions he is interested in attending, and what abstracts he is excited to see presented.
Rheumatology Training and Education: Dr. Janet Pope Interviews Trainees
Dr. Janet Pope meets with several rheumatology trainees to discuss training and education in this COVID-19 era. Interviewees includes Drs. Arpat Gantayet, Gabriel Jeyasingham, Gemma Cramarossa and Melissa Holdren.
Peter Nash drpnash
5 years ago
Association of Hydroxychloroquine Use with Development of Non-Alcoholic Fatty Liver Disease in Rheumatoid Arthritis https://t.co/3PrWlIGnB8 #RA #HCO #NASH - HCO decreases fatty liver
Peter Nash drpnash
5 years ago
Lymphomas Complicating Rheumatoid Arthritis: Results of a French Multi-Centre Case-Control Study https://t.co/NDk0LH5Kk6 #RA #lymphoma risk driven by increased disease activity
Peter Nash drpnash
5 years ago
Safety Profile of Baricitinib for the Treatment of Rheumatoid Arthritis up to 8.4 Years: An Updated Integrated Safety Analysis https://t.co/i456zSn6Ba #RA #Baricitinib #safety 13000 pt/yrs 8.4 yrs F/U no new safety signals VTE 0.5/100 pt yrs
Each pharmaceutical company has spent months and years preparing to present and highlight their featured clinical trials and abstracts at ACR 2020. This is our selection of their best studies for you to review and evaluate as part of your to-do list.
alexa meara lexmeara
5 years ago
COVID-19 use of dexamethasone- why does it work? When to use it ?Is it hyperferrintemic sepsis? Vs early MAS vs? More data needed but this why rheumatologists are needed!!! @RheumNow #ACR20 thank you dr. Rubin! https://t.co/MvQJGqsqu2
k dao KDAO2011
5 years ago
What is your top concern about the SARS-Co-V2 vaccine for rheum patients? @RheumNow #ACR20
Rheum Cat rheum_cat
5 years ago
@JYazdanyMD @UWRheum @r_burmester Black, et al - cont'd
277 atypical femur fx events
Risk increased w longer duration of bisphosphonate use
Risk decreased after bisphosphonate discontinuation
Asians had a higher risk than Whites.
#ACR20 #ACRambassador
Poster Hall